The stock of PhotoMedex Inc (NASDAQ:PHMD) is a huge mover today! About 111,334 shares traded hands or 34.89% up from the average. PhotoMedex Inc (NASDAQ:PHMD) has risen 57.65% since April 27, 2016 and is uptrending. It has outperformed by 52.42% the S&P500.
The move comes after 5 months negative chart setup for the $11.83 million company. It was reported on Nov, 30 by Barchart.com. We have $2.40 PT which if reached, will make NASDAQ:PHMD worth $709,800 less.
According to Zacks Investment Research, “Photomedex, Inc. develops, manufactures and markets therapeutic excimer laser-based instrumentation designed to treat psoriasis and vitiligo. They are also developing their technology for the treatment of other skin disorders. They’ve received the first Food and Drug Administration, or FDA, approval to market an excimer laser system, XTRAC system, for the treatment of psoriasis. They have commercially launched the XTRAC system in the United States.”
Insitutional Activity: The institutional sentiment decreased to 0.04 in Q2 2016. Its down 0.56, from 0.6 in 2016Q1. The ratio is negative, as 9 funds sold all PhotoMedex Inc shares owned while 6 reduced positions. 4 funds bought stakes while 5 increased positions. They now own 2.91 million shares or 39.23% less from 4.79 million shares in 2016Q1.
Nantahala Cap Mgmt Ltd Llc, a Connecticut-based fund reported 1.38M shares. Natl Bank Of America De has 37 shares for 0% of their US portfolio. Vanguard Gru has 191,075 shares for 0% of their US portfolio. Group Inc One Trading Limited Partnership, a Illinois-based fund reported 1,400 shares. Jpmorgan Chase And Commerce accumulated 803 shares or 0% of the stock. Stevens First Principles Inv Advsrs last reported 1,047 shares in the company. Blackrock Fund holds 2,484 shares or 0% of its portfolio. Geode Cap Lc reported 73,448 shares or 0% of all its holdings. Kcg reported 14,356 shares or 0% of all its holdings. The Kansas-based Creative Planning has invested 0% in PhotoMedex Inc (NASDAQ:PHMD). Bancorp Of Mellon accumulated 63,486 shares or 0% of the stock. Goldman Sachs Gp holds 0% of its portfolio in PhotoMedex Inc (NASDAQ:PHMD) for 49,157 shares. Carroll Financial Associates Incorporated has invested 0% of its portfolio in PhotoMedex Inc (NASDAQ:PHMD). Susquehanna Intl Ltd Liability Partnership accumulated 0% or 16,625 shares. Guggenheim Cap Ltd Liability Co accumulated 12,036 shares or 0% of the stock.
PHMD Company Profile
PhotoMedex, Inc., incorporated on December 28, 2010, is a global health services and products firm providing integrated disease management and solutions to dermatologists, professional aestheticians and consumers. The Firm provides services and products that address skin diseases and conditions, including acne and photo damage. It operates through three business divisions: Consumer segment, Physician Recurring segment and Professional segment. It provides skin health solutions to spa markets, as well as traditional retail, online and infomercial outlets for home-use products. Through its subsidiary, Radiancy, Inc., it offers a range of home-use devices under the no!no! brand, for various indications, including hair removal, acne treatment, skin rejuvenation and lower back pain. In addition, its professional product line includes offerings for acne clearance, skin tightening, psoriasis care and hair removal sold to physician clinics and spas. The Firm is also engaged in the development, manufacture and sale of surgical products, including free-beam and Contact Laser Systems for surgery.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.